Table 1 Clinicopathologic characteristics of ILC in this study
From: EZH2 expression in invasive lobular carcinoma of the breast
| EZH2 expression N(%) | P | |||||
|---|---|---|---|---|---|---|
| Total N(%) | 0% to 5% | 5% to 25% | 25% to 50% | >50% | ||
| Age at diagnosis | 0.255 | |||||
| <50 | 28 (57.1) | 3 (37.5) | 6 (75.0) | 2 (33.3) | 17 (63.0) | |
| ≤50 | 21 (42.9) | 5 (62.5) | 2 (25.0) | 4 (66.7) | 10 (37.0) | |
| Menstrual status | 0.472 | |||||
| Premenopausal | 27 (55.1) | 4 (50.0) | 6 (75.0) | 2 (33.3) | 15 (55.6) | |
| Postmenopausal | 22 (44.9) | 4 (50.0) | 2 (25.0) | 4 (66.7) | 12 (44.4) | |
| Body mass index | 0.647 | |||||
| Underweight (<20) | 3 (6.1) | 1 (12.5) | 0 (0) | 1 (16.7) | 1 (3.7) | |
| Normal (≥20, <25) | 29 (59.2) | 4 (50.0) | 6 (75.0) | 2 (33.3) | 17 (63.0) | |
| Overweight (≥25) | 17 (34.7) | 3 (37.5) | 2 (25.0) | 3 (50.0) | 9 (33.3) | |
| Side of primary tumor | 0.587 | |||||
| Left | 25 (51.0) | 5 (62.5) | 4 (50.0) | 4 (66.7) | 12 (44.4) | |
| Right | 21 (42.9) | 3 (37.5) | 3 (37.5) | 1 (16.7) | 14 (51.9) | |
| Bilateral | 3 (6.1) | 0 (0) | 1 (12.5) | 1 (16.7) | 1 (3.7) | |
| Multifocality | 0.981 | |||||
| Monofocal | 38 (77.6) | 6 (75.0) | 6 (75.0) | 5 (83.3) | 21 (77.8) | |
| Multifocal | 11 (22.4) | 2 (25.0) | 2 (25.0) | 1 (16.7) | 6 (22.2) | |
| T stage | 0.770 | |||||
| T1 | 22 (44.9) | 4 (50.0) | 5 (62.5) | 2 (33.3) | 11 (40.7) | |
| T2 | 23 (46.9) | 3 (37.5) | 3 (37.5) | 4 (66.7) | 13 (48.1) | |
| T3 | 4 (8.2) | 1 (12.5) | 0 (0) | 0 (0) | 3 (11.1) | |
| Lymph node metastasis | 0.403 | |||||
| N0 | 28 (57.1) | 6 (75.0) | 6 (75.0) | 4 (66.7) | 12 (44.4) | |
| N1 | 8 (16.3) | 1 (12.5) | 2 (25.0) | 0 (0) | 5 (18.5) | |
| N2 | 4 (8.2) | 1 (12.5) | 0 (0) | 0 (0) | 3 (11.1) | |
| N3 | 9 (18.4) | 0 (0) | 0 (0) | 2 (33.3) | 7 (25.9) | |
| Nuclear grade | 0.025 | |||||
| 1 | 7 (14.3) | 4 (50.0) | 2 (25.0) | 0 (0) | 1 (3.7) | |
| 2 | 32 (65.3) | 4 (50.0) | 5 (62.5) | 5 (83.3) | 18 (66.7) | |
| 3 | 10 (20.4) | 0 (0) | 1 (12.5) | 1 (16.7) | 8 (29.6) | |
| Estrogen receptor status | 0.629 | |||||
| Negative | 13 (26.5) | 1 (12.5) | 3 (37.5) | 1 (16.7) | 8 (29.6) | |
| Positive | 36 (73.5) | 7 (87.5) | 5 (62.5) | 5 (83.3) | 19 (70.4) | |
| Progesterone receptor status | 0.615 | |||||
| Negative | 10 (20.4) | 2 (25.0) | 2 (25.0) | 0 (0) | 6 (22.2) | |
| Positive | 39 (79.6) | 6 (75.0) | 6 (75.0) | 6 (100.0) | 21 (77.8) | |
| Cerb-B2 status | 0.410 | |||||
| Negative | 39 (79.6) | 5 (62.5) | 7 (87.5) | 4 (66.7) | 23 (85.2) | |
| Positive | 10 (20.4) | 3 (37.5) | 1 (12.5) | 2 (33.3) | 4 (14.8) | |
| p53 | 0.093 | |||||
| Negative | 37 (75.5) | 4 (50.0) | 5 (62.5) | 4 (66.7) | 24 (88.9) | |
| Positive | 12 (24.5) | 4 (50.0) | 3 (37.5) | 2 (33.3) | 3 (11.1) | |